-
An import alert from the regulator means that products from the facility meant for imports can be refused without a complete physical examination.
-
Pharmaceutical stocks have been under the US FDA cloud. Will 2017 fare better? CNBC-TV18's Latha Venkatesh & Sonia Shenoy asks Arpit Vyas, MD of Dishman Pharmaceuticals & Chemicals, Surajit Pal of Prabhudas Lilladher and Vishal Manchanda of Nirmal Bang Institutional Equities.
-
USFDA has issued notice to the Hyderabad unit of Aurobindo Pharma and calming the nerves of the investors Surajit Pal of Prabhudas Lilladher says that it is a non-event and there is no need to worry.
-
In conversation with CNBC-TV18, Surajit Pal, Prabhudas Lilladher, said Cipla's numbers are in line with the estimates but the company is still in the transition phase.
-
Surajit Pal of Prabhudas Lilladher said the brokerage will not be taking price action for pharma stocks. It will be difficult to prove the charges of price collusion, he added.
-
CNBC-TV18's Sumaira Abidi spoke with Sarabjit Kour Nangra, VP-Research at Angel Broking and Surajit Pal, AVP-Analyst Pharma at Prabhudas Lilladhar about healthcare sector at length.
-
Surajit Pal, Pharma Analyst at Prabhudas Lilladher told CNBC-TV18 that this is good news for Aurobindo as this plant has almost 26 percent of pending approvals which are important drivers for its US business.
-
Indian pharmaceutical companies Aurobindo and Intas are among the final contenders for Teva‘s generic drug business in UK. The strategy will help the companies expand their European business.
-
Surajit Pal of Prabhudas Lilladher talks about Sun Pharma and Glenmark's June quarter earnings.
-
Jubilant Life Sciences working on reducing its debt through internal accruals against taking fresh loan will serve well for its future growth says Surajit Pal, Prabhudas Lilladher.
-
Lupin on Wednesday received preliminary approval from the US FDA to market a generic equivalent of GlaxoSmithKline Plc‘s ViiV Healthcare‘s (ViiV) antiretroviral (ARV) Lexiva tablets in 700 milligram dosage form. This product was filed from the company's Goa plant which has run into a problem with the US FDA
-
Pharma companies are losing market share and such deals help them,says Surajit Pal of Prabhudas Lilladher.
-
Drugmaker's management highly unlikely to achieve guidance, says Surajit Pal, analyst at Prabhudas Lilladher.
-
The company has the highest margins within organised diagnostic sector, says market analyst Deven Choksey.
-
Hailing the government's move, Surajit Pal, pharma analyst at Prabhudas Lilladher, says the aim of regulation is to prevent rampant use of antibiotics. He says Abbott is likely to be severely impacted by the move as it has around 15.4 percent exposure to fixed-dosed combinations.
-
Sarabjit Kour Nangra, VP- Research, Angel Broking, believes it to be the Ranbaxy effect. However, she says 14.5 percent is very low, because after consolidation she was looking at closer to 30 percent.
-
Lupin reported a 1.1 percent fall in its fourth quarter net profit to Rs 547 crore as against Rs 553 crore in the corresponding quarter last fiscal. In an interview to CNBC-TV18, Abhishek Sharma, pharma analyst at IIFL, and Surajit Pal of Prabhudas Lilladher, analyse the results.
-
or the investors who are holding the stock should continue to hold it but fresh entry should be made only if it corrects from the current levels, says Surajit Pal, pharma analyst at Prabhudas Lilladher.
-
Surajit Pal, pharma analyst at Prabhudas Lilladher recommends holding Sun Pharma and feels that one may enter the stock on correction.
-
Surajit Pal, Pharma Analyst at Prabhudas Lilladher is of the view that one may accumulate Sun Pharmaceutical Industries.
-
The transaction is expected to close by August 2015.
-
The Competition regulator has given a 6 month window for the divestment process, and only after the divestment is complete will the deal get the final nod. But Surajit Pal believes the divestment process should be done by March.
-
Surajit Pal of Prabhudas Lilladher feels the pharma company's US sales will take atleast 18 months to recover. He fears that if USFDA issue is raised then UK MHRA too may act.
-
Ranbaxy Laboratories has turned profitable in the second quarter of current financial year. The company reported consolidated net profit of Rs 478 crore during the quarter as against loss of Rs 454 crore in the year-ago period.
-
Sarabjit Kaur Nangra of Angel Broking believes the company‘s current growth rate should not be difficult to maintain apart from big launches.
